



Developing Novel Endpoints for Premium Intraocular Lenses Workshop

Malvina B. Eydelman, M.D.

Director

Division of Ophthalmic and Ear, Nose and Throat Devices

ODE/CDRH/ FDA

Disclosure

- No Financial Relationships to Disclose

Cataract Surgery in U.S.

- Cataracts affect more than 22 million Americans and is expected to rise to 30 million by 2020¹
- Cataract surgery^{1,2}
 - >3 million performed per year in US and rising³ due to aging of population
 - It is the third most common procedure performed during outpatient surgery visits

¹ National The Eye Diseases Prevalence Research Group. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol 2004; 122:487–494

² ASD Reports 2012. www.asdreports.com/news.asp?pr_id=275

³ <http://health.usnews.com/health-news/news/articles/2013/10/11/more-americans-getting-cataract-surgery>

Monofocal Intraocular Lenses (IOLs)

- 1949 - First IOL implantation by Sir Harold Ridley
- 1970's – Investigational Device Exemption studies started in US
- 1981 - First IOL approved in US
- 1983 - IOL grid published¹
 - Safety and effectiveness criteria
 - Resulted in quicker approvals

¹Stark, et. al. The FDA Report on Intraocular Lenses. Ophthalmology, April 1983, Volume 90, Issue 4, pages 311-317

Monofocal IOLs: 2014

- 59 original PMAs approved
 - Most PMAs have supplements with IOL modifications
 - hundreds of different lenses on the U.S. market

Premium IOLs

- Correct more than the spherical error at distance
- First approval in US (multifocal) - 1997
- Currently approved in US:
 - 3 Multifocals
 - Alcon Acrysof ReStor; Tecnis Multifocal; AMO Array Multifocal
 - 1 Accommodating
 - B+L Crystalens
 - 4 Toric
 - STAAR Toric IOL; Alcon Acrysof Toric; B+L Trulign Toric; AMO Tecnis Toric
 - 2 Phakic
 - STAAR Visian ICL; Ophtec Aristan Myopia Lens

Premium IOLs in US

- “Increasing life expectancy, the need for people to work longer and the evolution of technology from laptops to tablets to cell phones all bode well for premium IOL conversions.”¹
- About 14% patients implanted with premium IOLs¹
- Industry motivation:
 - Large patient out of pocket cost leading to more revenue for the device
 - » Monofocal IOLS- Insurance reimbursement
 - » Premium IOLs - Out of pocket expense (\$1500 - \$5000 per eye, average \$3300)²
 - New Technology IOL (NTIOL) designation
 - » Designation by CMS leading to \$50 increased reimbursement per lens for 5 years after the decision

¹ <http://www.opththalmologymanagement.com/articleviewer.aspx?articleID=108644>

² <http://eyesurgeryeducation.org/surgery-options-presbyopia-lr-costs.php>


Premium IOLs: FDA

- Increasing number of submissions for premium IOLs
 - Significant technological advances in lens design
- Limited availability of FDA guidance or recognized standards
 - CDRH evaluates many submissions on a case-by-case basis
 - FDA and sponsors spend significant resources on repeat submissions
 - Delayed or limited benefit to other devices with similar characteristics

Premium IOLs: Current Roadblocks

- Lack of consensus:
 - Some pre-clinical issues
 - Best clinical trial design for some Premium IOLs
 - Appropriate safety and effectiveness endpoints
- Need for new categories for IOLs based on new optical properties and/or benefits to the patients

Developing Novel Endpoints for Premium Intraocular Lenses



FDA's Goals for Today's Workshop

- Extended Depth of Focus (EDOF) IOLs
 - Introduce a new category of IOLs for improved near and intermediate performance
 - Discuss some requirements for preclinical and clinical testing
 - Create a foundation for development of “Leap-Frog” Guidance for EDOF IOLs:
 - Mechanism via which we can share our initial thoughts regarding the content of premarket submissions for emerging technologies
 - Speed development and approval of future submissions

FDA's Goals for Today's Workshop (Continued)

- Discuss current limitation of endpoints for all premium IOLS
- Assess pros and cons of various methodologies for each endpoint
- Obtain recommendations on the best way to develop the needed endpoints
 - Consensus statements
 - Preclinical or clinical studies
- Facilitate collaboration of all interested parties to work together to increase the efficiency of tool development through joint efforts
 - Could potentially be used in multiple device development programs (beyond Premium IOLs)
- Deliver transformational change by combining the best internal and external talent to shorten the time from conception to market



U.S. Food and Drug Administration
Protecting and Promoting Public Health



You are the Change Agents!

